News
QGEN
50.90
-0.31%
-0.16
Qiagen’s Greener Lab Automation Push And What It Could Mean For Growth
Simply Wall St · 4h ago
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Humana (HUM)
TipRanks · 9h ago
Goldman Sachs Discloses 2.87% Stake in QIAGEN via AFM Filing
TipRanks · 1d ago
BlackRock Lifts Stake in Qiagen to Over 10% Capital Interest
TipRanks · 1d ago
Goldman Sachs Discloses 3.42% Voting Stake in QIAGEN
TipRanks · 1d ago
Goldman Sachs Discloses 3.06% Stake in Qiagen via AFM Filing
TipRanks · 1d ago
Goldman Sachs Raises Total Voting Rights in Qiagen NV to 3.06%
Reuters · 1d ago
Qiagen Automation Push And Sustainability Aims Meet Undervalued Stock Story
Simply Wall St · 1d ago
Qiagen price target raised to $52 from $50 at UBS
TipRanks · 3d ago
Qiagen: Slower Core Growth and Back-Half-Loaded Targets Keep Risk/Reward Balanced at Hold
TipRanks · 3d ago
Qiagen NV Publishes Transcript of Fourth Quarter and Full-Year 2025 Results Call
Reuters · 3d ago
Qiagen NV veröffentlicht Transkript zur Telefonkonferenz zu den Ergebnissen des vierten Quartals und Geschäftsjahres 2025
Reuters · 3d ago
Weekly Report: what happened at QGEN last week (0202-0206)?
Weekly Report · 3d ago
Assessing Qiagen (QGEN) Valuation After Recent Share Price Momentum And Modest Undervaluation Estimate
Simply Wall St · 3d ago
QIAGEN Earnings Call: Growth Pillars Offset Near-Term Drag
TipRanks · 4d ago
Goldman Sachs hält 2,95 % der Stimmrechte an Qiagen NV
Reuters · 6d ago
Goldman Sachs Increases Potential Voting Rights in Qiagen NV to 2.95%
Reuters · 6d ago
Qiagen Is Maintained at Overweight by JP Morgan
Dow Jones · 6d ago
Qiagen Price Target Raised to $60.00/Share From $55.00 by JP Morgan
Dow Jones · 6d ago
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $60
Benzinga · 6d ago
More
Webull provides a variety of real-time QGEN stock news. You can receive the latest news about Qiagen through multiple platforms. This information may help you make smarter investment decisions.
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.